Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cell Infusion in AML
NCT04221971Phase 1Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2020
- Primary completion
- Apr 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Natural Killer Cells in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Peking University People's Hospital. Primary endpoint: Number of participants with treatment-related adverse events at 2 months. Status: unknown.
02
Drugs
Natural Killer Cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04221971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221971.